Andrew Biankin

Last updated

Andrew Biankin

AO
Andrew Biankin Headshot.jpg
Born1966
Years active1990s-Now

Andrew Victor Biankin AO is a Scotland-based Australian clinician-scientist, best known for his work on enabling precision oncology in learning healthcare systems by integrating discovery, preclinical and clinical development to accelerate novel therapeutic strategies, and developing standardised pan-cancer assays for use by healthcare systems and researchers worldwide.

Contents

Biankin, who works as the Regius Professor of Surgery at the University of Glasgow, was made an Officer of the Order of Australia (AO) in the Queen’s Birthday Honours List for 2019, for distinguished service to medical research, and to the treatment of pancreatic cancer, [1] [2] [3] [4] [5] [6] [7] [8] as a clinician-scientist.

Biankin is a Fellow of the Royal Society of Edinburgh and a Fellow of the Academy of Medical Sciences. [9] [10] He has written over 160 articles in major medical journals relating to cancer, genomics and precision medicine. [11]

Career

The eldest of three sons, Biankin was born in Sydney’s western suburbs where his immigrant parents introduced him to projects on their weekend farm.

Initially enrolling in a pharmacy degree in 1983, Biankin then transferred to medicine the following year, graduating with his medical degree from the University of New South Wales in 1992.

During his medical degree, he also took a year off to do a science research degree, and in another year’s ‘sabbatical’, learned to play the violin.

His medical internship was followed by an intensive period in the emergency department of a large Sydney hospital where his surgical skills were in constant demand. Completing his surgical training, Biankin began to specialise in surgery for pancreatic cancer. Experiencing the unpredictability of pancreatic cancer and the high mortality rate of pancreatic cancer patients, he decided to conduct research in pancreatic cancer at the Garvan Institute of Medical Research in Sydney under Professor Rob Sutherland, [12] Director of the Cancer Research Program.

His PhD project was an early personalised medicine approach that looked at why patients respond differently to treatment, despite the similarity of the tumours under the microscope. He continued to hone his surgical skills in the clinic. He finished his PhD in translational research at the end of 2002.

Translational research

Following a postdoctoral position at Johns Hopkins University, USA, to further develop his scientific skills, he returned to Sydney in 2004 to establish a pancreatic cancer program at the Garvan Institute, setting up the New South Wales Pancreatic Cancer Network and then the Australian Pancreatic Cancer Network. With senior surgeon Dr Neil Merrit, Biankin established a hepatobiliary unit at Bankstown Hospital, Sydney, and in 2007, with a focus on translational research, began integrating this clinical practice with emerging precision oncology research.

In 2009, Biankin and Sean Grimmond established the Australian Pancreatic Cancer Genome Initiative (APGI) [13] – the pancreatic cancer arm of the International Cancer Genome Consortium (ICGC). The APGI went on to map and upload the complete DNA read-outs for around 400 pancreatic cancers to the ICGC project, making it one of the largest sets of whole genome sequences for any cancer type. This work took pancreatic cancer from one of the least genetically characterised cancers to one of the best.

As part of this work, they received a A$30M infrastructure grant to conduct genomic sequencing in Australia to address issues in pancreatic cancer and to develop the pathways and the questions that could be addressed to understand the underlying molecular complexity and variability of pancreatic cancer and what was clinically and translationally relevant, and look for new targets for future therapies.

Pan-cancer assays

Following the death of his mentor, Sutherland, from pancreatic cancer in 2012, Biankin focused on analytics and the importance of developing a molecular diagnostic/prognostic test that could guide treatment and the placement of patients into clinical trials. To this end, Biankin co-founded Cure Forward in the USA, where he was the chief medical and scientific advisor from 2012 until 2017, but encountered issues of the reliability, timeliness and cost of existing tests and scalability.

In 2013, as Regius Professor of Surgery, Biankin also took up the Directorship of the Wolfson Wohl Cancer Research Centre at the University of Glasgow, [14] [15] and established the Glasgow Precision Oncology Laboratory (GPOL) in 2016 to develop a molecular test to drive his planned precision oncology clinical trials program for pancreatic cancer - Precision-Panc.

Analysing data from ICGC and The Cancer Genome Atlas, Biankin and his team realised it would be possible to design a molecular/genomic test for 95% of solid tumours across the range of cancers and in 2019 the Glasgow Cancer Test was released for assessment in the real-world setting of the NHS and from November 2019 became available for research, including for clinical trials, from Agilent Technologies, which holds a non-exclusive global distribution licence. There is also a Glasgow Cancer Test for haematological cancers.

Learning healthcare systems

The Glasgow Cancer Test was designed to be affordable for use in a public healthcare system and requires no special preparation of samples. As part of embedded research in a learning healthcare system, standardised broad genomic profiling, such as the Glasgow Cancer Test, can provide the large datasets that researchers need to continually refine current treatments and develop new ones as part of precision medicine.

Biankin has said that "While this is an entirely new way of looking at the world of drug development and delivery, there are no options. The pressures of an ageing population mean that we must rethink the way we approach healthcare." [16] "Finding the right way for precision medicine to work in healthcare systems is a bit like breaking a wartime code – the stakes are high and time is against us. Breaking the cancer code that connects the cancer genomes to the patient's treatment is what drives me as a scientist and a doctor."

Global data sharing

In 2018 Biankin took over as Executive Director and Chairman of the International Cancer Genome Consortium [17] [18] and set about developing the Accelerated Research for Genomic Oncology (ICGC-ARGO) initiative.

ICGC is an international network of cancer clinicians, researchers and clinical trials groups and the ARGO initiative aims to capture, aggregate and harmonise the rich, longitudinal, clinical data of some 200,000 people to provide a million patient-years of precision oncology knowledge in a manner that allows for broad, but ethically responsible, data sharing and research.

The aim with ICGC-ARGO is to change culture and practice on an international level with support for the embedding of clinical trials in learning health systems and the development of a standardised assays used in the clinical trials of the consortium to produce rich comparable and shareable longitudinal data globally

Related Research Articles

<span class="mw-page-title-main">Roswell Park Comprehensive Cancer Center</span> Hospital in New York, United States of America

Roswell Park Comprehensive Cancer Center is a cancer research and treatment center located in Buffalo, New York. Founded by surgeon Roswell Park in 1898, the center was the first in the United States to specifically focus on cancer research. The center is usually called Roswell Park in short. The center, which conducts clinical research on cancer as well as the development new drugs, provides advanced treatment for all forms of adult and pediatric cancer, and serves as a member of the National Comprehensive Cancer Network. Roswell Park Comprehensive Cancer Center is as of 2019, the only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center".

<span class="mw-page-title-main">Personalized medicine</span> Medical model that tailors medical practices to the individual patient

Personalized medicine, also referred to as precision medicine, is a medical model that separates people into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. The terms personalized medicine, precision medicine, stratified medicine and P4 medicine are used interchangeably to describe this concept though some authors and organisations use these expressions separately to indicate particular nuances.

MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. It gives a binary result, high-risk or low-risk classification, and helps physicians determine whether or not a patient will benefit from chemotherapy. Women with a low risk result can safely forego chemotherapy without decreasing likelihood of disease free survival. MammaPrint is part of the personalized medicine portfolio marketed by Agendia.

The International Cancer Genome Consortium (ICGC) is a voluntary scientific organization that provides a forum for collaboration among the world's leading cancer and genomic researchers. The ICGC was launched in 2008 to coordinate large-scale cancer genome studies in tumours from 50 cancer types and/or subtypes that are of main importance across the globe.

Geriatric oncology is a branch of medicine that is concerned with the diagnosis and treatment of cancer in the elderly, usually defined as aged 65 and older. This fairly young but increasingly important subspecialty incorporates the special needs of the elderly into the treatment of cancer.

<span class="mw-page-title-main">Oncology</span> Branch of medicine dealing with, or specializing in, cancer

Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:

Dr. Paul R. Billings is a distinguished American doctor, lecturer, researcher, professor, and consultant on genetic information. His research interests include the impact of genomic data on society, the integration of genomics with diagnostics in health and medical care, and individualized genomic medicine. He is the author of over 250 publications and has appeared on talk shows such as The Oprah Winfrey Show and 60 Minutes. He is currently the CEO and Director of Biological Dynamics.

The Pancreatic Cancer Action Network (PanCAN) is a United States-based 501(c)(3) charity that funds research, provides patient/caregiver support, conducts community outreach and advocates for increased federal research funding for those affected by pancreatic cancer.

<span class="mw-page-title-main">Binaytara Foundation</span> U.S. nonprofit organization

The Binaytara Foundation (BTF) was established in 2007 by Dr. Binay Shah and wife Tara Shah with the goal of promoting health and education in underprivileged societies. The BTF is a Washington State nonprofit organization exempt from taxation pursuant to Section 501(c)(3) of the Internal Revenue Code. BTF has founded multiple programs in underdeveloped and developing countries to improve access to healthcare. Recent accomplishments include building a 25-bed cancer hospital in Nepal in 2018 and breaking ground on their new 200-bed facility in 2022.

The 100,000 Genomes Project is a now-completed UK Government project managed by Genomics England that is sequencing whole genomes from National Health Service patients. The project is focusing on rare diseases, some common types of cancer, and infectious diseases. Participants give consent for their genome data to be linked to information about their medical condition and health records. The medical and genomic data is shared with researchers to improve knowledge of the causes, treatment, and care of diseases.

Foundation Medicine, Inc. is an American company based in Cambridge, Massachusetts, which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas.

<span class="mw-page-title-main">Alan Coates</span> Australian clinical oncologist

Alan Stuart Coates is an Australian professor of clinical oncology, medical researcher and administrator. He was the inaugural CEO of the Cancer Council Australia (1998–2006), former president of the Clinical Oncological Society of Australia (COSA), and co-chair of the St. Gallen International Breast Cancer Conference. He was also the first non-American to be elected to the board of directors of the American Society of Clinical Oncology.

<span class="mw-page-title-main">Elizabeth Jaffee</span> American oncologist

Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.

Personalized onco-genomics (POG) is the field of oncology and genomics that is focused on using whole genome analysis to make personalized clinical treatment decisions. The program was devised at British Columbia's BC Cancer Agency and is currently being led by Marco Marra and Janessa Laskin. Genome instability has been identified as one of the underlying hallmarks of cancer. The genetic diversity of cancer cells promotes multiple other cancer hallmark functions that help them survive in their microenvironment and eventually metastasise. The pronounced genomic heterogeneity of tumours has led researchers to develop an approach that assesses each individual's cancer to identify targeted therapies that can halt cancer growth. Identification of these "drivers" and corresponding medications used to possibly halt these pathways are important in cancer treatment.

Rosalind Anne Eeles is a Professor of Oncogenetics at the Institute of Cancer Research and clinician at the Royal Marsden NHS Foundation Trust. She is a leader in the field of genetic susceptibility to prostate cancer, and is known for the discovery of 14 genetic variants involved in prostate cancer predisposition. According to ResearchGate, Eeles has published more than 500 articles in peer-reviewed journals, with over 34,000 citations and an h-index of 92. Eeles was elected a Fellow of the Academy of Medical Science in 2012. She was awarded a National Institute for Health Research Senior Investigator Emeritus in 2014.

Sophia Genetics is a data-driven medicine software company with headquarters in Lausanne, Switzerland and Boston, Massachusetts. It provides genomic and radiomic analysis for hospitals, laboratories, and biopharma institutions. The company was ranked among the 50 smartest companies by the MIT Technology Review in 2017. The company went public on the Nasdaq in 2021, floating at $1.1B.

The University of Glasgow's Glasgow Precision Oncology Laboratory (GPOL) is a molecular research facility that partners with the NHS and industry to perform research into the development of novel therapeutic strategies, the creation of pan-cancer genomic assays and provide knowledge transfer for healthcare systems to enable them to develop landscapes for therapeutic testing in cancer.

Levi A. Garraway is an American oncologist. His research team was among the first to adapt genomics technologies to enable scalable, high-throughput clinical approaches to cancer gene mutation profiling. As a result, he was inducted into the American Society for Clinical Investigation, American Association for Cancer Research, and National Academy of Medicine.

<span class="mw-page-title-main">Ruth March</span> British genomic scientist

Ruth Eleanor March is a British genomic scientist who is senior vice president of precision medicine at AstraZeneca. She specialises in precision medicine and oncology. During the COVID-19 pandemic, March developed a diagnostic test for COVID-19.

Precision diagnostics is a branch of precision medicine that involves precisely managing a patient's healthcare model and diagnosing specific diseases based on customized omics data analytics.

References

  1. ↑ Goodyer, Paula (24 August 2006) The hidden killer, The Sydney Morning Herald , Nine Entertainment Co. Retrieved 12 June 2019.
  2. ↑ Hall, Ashley (15 April 2010) Australian researchers release first genetic road maps for pancreatic cancer, AM , Australian Broadcasting Corporation. Retrieved 12 June 2019.
  3. ↑ (25 October 2012) Aussies crack pancreatic cancer genetic mystery, news.com.au , News Corp Australia. Retrieved 12 June 2019.
  4. ↑ Grimm, Nick (26 February 2015) Medical breakthrough: Australian researchers map the genome for pancreatic cancer, The World Today , Australian Broadcasting Corporation. Retrieved 12 June 2019.
  5. ↑ Campsie, Alison (13 May 2016) Meet Scotland's top scientists fighting world's worst diseases, The Scotsman , JPIMedia. Retrieved 12 June 2019.
  6. ↑ Munro, Alistair (24 March 2017) Glasgow scientists leading pancreatic cancer treatment, The Scotsman, JPIMedia. Retrieved 12 June 2019.
  7. ↑ Reporter, Scotsman (25 December 2018) Glasgow experts lead UK pancreatic cancer research, The Scotsman, JPIMedia. Retrieved 12 June 2019.
  8. ↑ Summers, Lisa (25 April 2019) Cancer test treats patients with precision, BBC News , British Broadcasting Corporation. Retrieved 12 June 2019.
  9. ↑ Fellow: Andrew Biankin, Royal Society of Edinburgh. Accessed 12 June 2019.
  10. ↑ Fellow: Andrew Biankin, Academy of Medical Sciences. Accessed 12 June 2019.
  11. ↑ Team: Andrew Biankin, Glasgow Precision Oncology Laboratory. Accessed 12 June 2019.
  12. ↑ Sutherland, Rob (24 January 2013). "Cancer work recognised worldwide". Sydney Morning Herald. Retrieved 27 March 2020.
  13. ↑ "The APGI Story". Australian Pancreatic Genome Initiative. 2016. Retrieved 27 March 2020.
  14. ↑ Staff: Andrew Biankin, Institute of Cancer Sciences, University of Glasgow. Accessed 12 June 2019.
  15. ↑ "Award ID: 2004632, Australian Honours Search Facility, Department of the Prime Minister and Cabinet, Australian Government. Accessed 12 June 2019".
  16. ↑ Biankin, Andrew (November 2019). "Andrew Biankin biography". Glasgow Precision Oncology Laboratory. Retrieved 31 March 2020.
  17. ↑ Prof Andrew Biankin, Cure Cancer website. Accessed 12 June 2019.
  18. ↑ "ICGC homepage announcement 16 May 2018".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.